摘要
目的:分析258例肺癌骨转移患者的临床和病理资料,探讨综合治疗疗效及相关预后因素。方法:回顾性分析2006年2月至2008年2月间258例同济大学附属上海市肺科医院肺癌骨转移患者综合治疗的疗效,生存率用Kaplan-Meier法计算,单因素分析采用Log-rank方法,多因素分析采用Cox回归模型。结果:全组1年、2年生存率分别为52.3%、26.4%,中位生存时间为12.6个月。单因素分析显示初诊时PS评分、骨转移灶数目、骨转移后是否化疗、骨转移时血清AKP及CA242与预后相关(P<0.05)。多因素分析结果显示初诊时临床分期、骨转移时血清AKP水平、骨转移数目及初诊时PS评分为独立预后因子。结论:肺腺癌骨转移发生率最高,骨转移好发部位依次是椎骨、骨盆骨和肋骨。初诊时临床分期、骨转移时血AKP水平、骨转移数目及初诊时PS评分为影响肺癌骨转移患者疗效的独立预后因素。
To evaluate the outcome and prognosis of lung cancer patients with bony metastases wno underwent multimodal treatment. Methods： The data of 258 lung oancer patients with bony metastases were analyzed retrospectively. The survival rates were calculated using the Kaplan - Meier method. The log-rank method was used for univariate analysis, and the Cox regression model was used for multivariate analysis. Clinical data of 258 lung cancer patients with bony metastases admitted to the Shanghai Hospital of Pulmonary Diseases from February 2006 to February 2008 were retrospectively analyzed. Results： The one and two-year survival rates of the patients were 52.6% and 26.5%, respectively. The median survival time was 12.6 months for patients with bony metastases from lung cancer. Univariate analysis showed that the PS score, number of osseous metastases, possibility of chemotherapy after metastasis, as well as serum AKP and CA242 levels were prognostic factors （ P 〈 0.001 ）. Multivariate analysis indicated that the clinical stage, AKP level, chemotherapy after metastasis, and PS score were independent prognostic factors. Conclusion： The bony metastasis of lung adenocarcinoma ranks first in the incidence of tumor metastases. The predilection sites of bony metastases are in the order of spine, pelvis, and ribs. The clinical stage at first visit, serum AKP, number of osseous metastasis, and PS score at first visit greatly influence the prognosis of patients with bony metastasis from lung cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2012年第13期914-918,共5页
Chinese Journal of Clinical Oncology
关键词
肺癌
综合治疗
骨转移
预后因素
Lung cancer
Multimodal treatment
Bony metastasis, Prognostic factors
